Your browser doesn't support javascript.
loading
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Girotti, Maria Romina; Lopes, Filipa; Preece, Natasha; Niculescu-Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence; Whittaker, Steven; Saturno, Grazia; Viros, Amaya; Pedersen, Malin; Suijkerbuijk, Bart M J M; Menard, Delphine; McLeary, Robert; Johnson, Louise; Fish, Laura; Ejiama, Sarah; Sanchez-Laorden, Berta; Hohloch, Juliane; Carragher, Neil; Macleod, Kenneth; Ashton, Garry; Marusiak, Anna A; Fusi, Alberto; Brognard, John; Frame, Margaret; Lorigan, Paul; Marais, Richard; Springer, Caroline.
Affiliation
  • Girotti MR; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Lopes F; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Preece N; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Niculescu-Duvaz D; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Zambon A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Davies L; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Whittaker S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Saturno G; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Viros A; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Pedersen M; Targeted Therapy Team, The Institute of Cancer Research, London SW3 6JB, UK.
  • Suijkerbuijk BM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Menard D; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • McLeary R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Johnson L; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Fish L; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  • Ejiama S; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Sanchez-Laorden B; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Hohloch J; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Carragher N; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK.
  • Macleod K; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK.
  • Ashton G; Histology Unit, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Marusiak AA; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Fusi A; University of Manchester, Christie NHS Foundation Trust, Manchester M20 4BX, UK.
  • Brognard J; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
  • Frame M; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK.
  • Lorigan P; University of Manchester, Christie NHS Foundation Trust, Manchester M20 4BX, UK.
  • Marais R; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK. Electronic address: richard.marais@cruk.manchester.ac.uk.
  • Springer C; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK. Electronic address: caroline.springer@icr.ac.uk.
Cancer Cell ; 27(1): 85-96, 2015 Jan 12.
Article in En | MEDLINE | ID: mdl-25500121
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phenylurea Compounds / Pyrazines / Src-Family Kinases / Drug Resistance, Neoplasm / Proto-Oncogene Proteins B-raf / Protein Kinase Inhibitors / Melanoma / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Year: 2015 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phenylurea Compounds / Pyrazines / Src-Family Kinases / Drug Resistance, Neoplasm / Proto-Oncogene Proteins B-raf / Protein Kinase Inhibitors / Melanoma / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Year: 2015 Type: Article